Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

  • G. Folprecht - , Department of internal Medicine I (Author)
  • M. Nowacki - (Author)
  • I. Lang - , National Institute of Oncology (Author)
  • S. Cascinu - , Marche Polytechnic University (Author)
  • I. Shchepotin - (Author)
  • J. Maurel - , University of Barcelona (Author)
  • P. Rougier - , Université de Versailles Saint-Quentin-en-Yvelines (Author)
  • D. Cunningham - , Royal Marsden NHS Foundation Trust (Author)
  • A. Zubel - , Merz GmbH & Co. KGaA (Author)
  • E. Van Cutsem - , KU Leuven (Author)

Details

Original languageEnglish
Number of pages2
JournalJournal of clinical oncology
Volume27
Issue number15
Publication statusPublished - 20 May 2009
Peer-reviewedYes

Conference

Title45th Annual Meeting of the American-Society-of-Clinical-Oncology
Duration29 May - 2 June 2009
CityOrlando
CountryUnited States of America

External IDs

ORCID /0000-0002-9321-9911/work/142252009

Keywords

Sustainable Development Goals